Inactive Instrument

News CEL-SCI Corporation Nyse

Equities

US1508374097

End-of-day quote Nyse Other stock markets
- ^USD	-

20/06	CEL-SCI Corporation Presents Head & Neck Cancer Data At Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated with Multikine in the Target Population	CI
15/05	CEL-SCI Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CEL-SCI Corporation Presents Head & Neck Cancer Data At Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated with Multikine in the Target Population	20/06	CI
CEL-SCI Presents Head and Neck Cancer Data at Iddst Annual Congress in Budapest, Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population	19/06	AQ
CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population	18/06	BU
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor	06/06	BU
Cel-Sci: Fiscal Q2 Earnings Snapshot	16/05	AQ
CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results	16/05	BU
CEL-SCI Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	16/05	CI
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head and Neck Cancer	09/05	AQ
Cel-Sci Gets US FDA Clearance to Proceed With Confirmatory Study for Cancer Drug Multikine	09/05	MT
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer	08/05	BU
CEL-SCI Corporation Announces Significantly Positive Outcome from its Recent Meeting with U.S. Food and Drug Administration Regarding Path to Approval for its First-Line Investigational Cancer Immunotherapy Multikine	08/05	CI
CEL-SCI Corporation Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer	08/05	CI
CEL-SCI Appoints Mario Gobbo to Its Board of Directors	23/04	BU
CEL-SCI Corporation Appoints Mario Gobbo as Board of Directors	23/04	CI
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology	19/03	BU
CEL-SCI Corporation Issues Letter to Shareholders	06/03	BU
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results	15/02	BU
Cel-Sci: Fiscal Q1 Earnings Snapshot	15/02	AQ
CEL-SCI Corporation Reports Earnings Results for the First Quarter Ended December 31, 2023	15/02	CI
Cel-Sci Closes $7.8 Million Share Offering	13/02	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News CEL-SCI Corporation Nyse

Equities

US1508374097

Summary

Filters